| Date | Title | Description | |
|---|---|---|---|
| 22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
| 29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 May 2026 | Announcement of general shareholders’ meeting | The Company announces the calling of its 2026 Ordinary General Shareholder´s Meeting. | Download |
| 01 Apr 2026 | On corporate transactions | ROVI announces the closing of the Asset Purchase Agreement entered into in September 2025 for the acquisition of a pharmaceutical manufacturing facility in Phoenix, Arizona (USA) | Download |
| 25 Feb 2026 | Annual Corporate Governance Report | The Company submits the Annual Corporate Governance Report for fiscal year 2025. | Download |
| 25 Feb 2026 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2025 annual report regarding remuneration of the members of the Board of Directors. | Download |
| 18 Nov 2025 | On business and financial situation | The Company releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2012 | Información sobre resultados (2) | Download | |
| 21 Feb 2012 | Información sobre resultados | Download | |
| 21 Feb 2012 | Informe Anual de Gobierno Corporativo | Download | |
| 15 Feb 2012 | Cambios en política de inversión, áreas de negocio y líneas de productos | Download | |
| 22 Dec 2011 | Composición del Consejo de Administración | Download |